Kymab Announces Presentations at the 24th EHA Annual Congress

Cambridge, UK; June 13, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced that two abstracts describing KY1049, Kymab’s fully-human Factor VIII (FVIII)-mimetic bispecific antibody, will be presented at the 24th European Hematology Association Annual Congress in Amsterdam, being held June 13-16. An abstract containing a preclinical evaluation of KY1049 will be presented as an oral presentation. In addition, a poster presentation introduces Kymab’s proprietary IntelliSelect Bispecifics platform that can generate diverse and extensive panels of fully human, common light-chain bispecific antibodies. Developed using high-throughput hemostatic assays, KY1049 is the first CLC bispecific molecule produced using the IntelliSelect Bispecifics platform.